WEBThis infographic explains what biosimilars are, what conditions they treat, and the similarities and differences between biosimilars, the original biologic, and generic drugs. Keywords
Over 50 Biosimilars in 10 years — and the Pipeline is Still Full
WEBJul 3, 2024 · In their first three years after market entry (study years 2013-2020), biosimilars in the United States have consistently been 38% more likely to be covered by employer-sponsored plans than by Medicare Part D plans, Bertuzzi and Maini wrote in their Health Affairs study.
Biosimilars in the United States 2023-2027 - IQVIA
WEBJan 31, 2023 · In this report, the current state of the biologics market in the United States and share of the market facing biosimilar competition are assessed. Factors impacting biosimilar uptake, including reimbursement and provider type, and the impact of biosimilars on molecule volume and price are evaluated.
- [PDF]
Biosimilar Basics
WEBBiosimilars are safe and effective biologic medications for treating many illnesses such as chronic skin and bowel diseases, arthritis, kidney conditions and cancer. Biologic medications are generally made from natural sources and developed using advanced.
Biosimilars in the United States 2020–2024 - IQVIA
WEBSep 29, 2020 · This IQVIA Institute report assess the current state of the biologics market in the United States. The market is segmented into the part currently facing biosimilar competition, parts that are not, and those molecules …
Toolkit | Biosimilars Council | Leading Resource on Biosimilars
WEBThe Biosimilars Handbook is the premier resource for biosimilar education. Choose from four different tracks – medical professional, patient, insurer or policymaker – to learn how biosimilars and interchangeable biologic products can decrease costs and increase access to lifesaving medicines.
Biosimilars to continue rapid growth over the next decade
WEBAccording to IQVIA’s Forecast Link, biosimilar value grew at a CAGR of 78% between 2015 and 2020, reaching approximately $17.9 bn in 2020 and is expected to continue growing at a CAGR of 15% between 2020 and 2030 reaching an …
WEBJul 20, 2020 · WHAT ARE. BIOSIMILARS? development and manufacturing processes. They are often exp. Biosimilars are FDA-approved alternatives to reference biologics . – much like generic drugs – that provide treatment options for patients who need biologic medicines to manage their conditions. 2% Of U.S. patients use biologics. 50%
Biosimilars Basics for Patients - FDA
WEBBiosimilars are safe and effective medications for treating many illnesses such as arthritis and cancer. Learn about biosimilars and how they benefit patients.
FACTSHEETS & INFOGRAPHICS - Biosimilars | Patient Resource …
WEBThis infographic introduces key concepts related to biosimilars, including an introduction to biologics, what “highly similar” means, what “no clinically meaningful differences” means and how biosimilars are evaluated and monitored.